These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 9403608

  • 1. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA, Worley S, Veriabo NJ, Lance ET, Mack S, Schaible T, Weisman HF, Jordan RE.
    Circulation; 1997 Dec 02; 96(11):3860-6. PubMed ID: 9403608
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
    Mascelli MA, Kleiman NS, Marciniak SJ, Damaraju L, Weisman HF, Jordan RE.
    Am Heart J; 2000 Apr 02; 139(4):696-703. PubMed ID: 10740154
    [Abstract] [Full Text] [Related]

  • 3. Rapid platelet-function assay: an automated and quantitative cartridge-based method.
    Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, Coller BS.
    Circulation; 1999 Feb 09; 99(5):620-5. PubMed ID: 9950658
    [Abstract] [Full Text] [Related]

  • 4. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 5. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.
    Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE.
    Circulation; 1998 May 05; 97(17):1680-8. PubMed ID: 9591761
    [Abstract] [Full Text] [Related]

  • 6. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G.
    J Thromb Thrombolysis; 2001 Apr 05; 11(2):99-110. PubMed ID: 11406724
    [Abstract] [Full Text] [Related]

  • 7. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.
    Coller BS, Lang D, Scudder LE.
    Circulation; 1997 Feb 18; 95(4):860-7. PubMed ID: 9054743
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.
    Circulation; 1999 Apr 20; 99(15):1951-8. PubMed ID: 10208997
    [Abstract] [Full Text] [Related]

  • 11. Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction.
    Desch S, Siegemund A, Scholz U, Adam N, Eitel I, de Waha S, Fürnau G, Lurz P, Wetzel S, Schuler G, Thiele H.
    Clin Res Cardiol; 2012 Feb 20; 101(2):117-24. PubMed ID: 22015616
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition.
    Osende JI, Fuster V, Lev EI, Shimbo D, Rauch U, Marmur JD, Richard M, Varon D, Badimon JJ.
    Circulation; 2001 Mar 20; 103(11):1488-91. PubMed ID: 11257073
    [Abstract] [Full Text] [Related]

  • 14. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
    Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, Miller DP, Califf RA, Topol EJ.
    Am J Cardiol; 1998 Jul 01; 82(1):7-12. PubMed ID: 9671000
    [Abstract] [Full Text] [Related]

  • 15. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
    Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, Kleiman NS, Tcheng JE, Califf R, Lincoff AM.
    J Am Coll Cardiol; 2000 Aug 01; 36(2):381-6. PubMed ID: 10933346
    [Abstract] [Full Text] [Related]

  • 16. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
    Abernethy DR, Pezzullo J, Mascelli MA, Frederick B, Kleiman NS, Freedman J.
    Clin Pharmacol Ther; 2002 Mar 01; 71(3):186-95. PubMed ID: 11907493
    [Abstract] [Full Text] [Related]

  • 17. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, Michelson AD.
    Am Heart J; 2003 Feb 01; 145(2):e6. PubMed ID: 12595861
    [Abstract] [Full Text] [Related]

  • 18. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
    Verdoia M, Pergolini P, Camaro C, Restifo M, Rolla R, Schaffer A, Di Giovine G, Marino P, Bellomo G, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group (NAS).
    Blood Coagul Fibrinolysis; 2013 Jun 01; 24(4):411-8. PubMed ID: 23412353
    [Abstract] [Full Text] [Related]

  • 19. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
    Turner NA, Moake JL, Kamat SG, Schafer AI, Kleiman NS, Jordan R, McIntire LV.
    Circulation; 1995 Mar 01; 91(5):1354-62. PubMed ID: 7867173
    [Abstract] [Full Text] [Related]

  • 20. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK, Mahrholdt H, Schröder S, Baumbach A, Oberhoff M, Herdeg C, Karsch KR.
    Am Heart J; 1999 Feb 01; 137(2):234-40. PubMed ID: 9924156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.